amifampridine has been researched along with Neuromuscular Junction Diseases in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
Neuromuscular Junction Diseases: Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burns, TM | 1 |
| Smith, GA | 1 |
| Allen, JA | 1 |
| Amato, AA | 1 |
| Arnold, WD | 1 |
| Barohn, R | 1 |
| Benatar, M | 1 |
| Bird, SJ | 1 |
| Bromberg, M | 1 |
| Chahin, N | 1 |
| Ciafaloni, E | 1 |
| Cohen, JA | 1 |
| Corse, A | 1 |
| Crum, BA | 1 |
| David, WS | 1 |
| Dimberg, E | 1 |
| Sousa, EA | 1 |
| Donofrio, PD | 1 |
| Dyck, PJ | 1 |
| Engel, AG | 1 |
| Ensrud, ER | 1 |
| Ferrante, M | 1 |
| Freimer, M | 1 |
| Gable, KL | 1 |
| Gibson, S | 1 |
| Gilchrist, JM | 1 |
| Goldstein, JM | 1 |
| Gooch, CL | 1 |
| Goodman, BP | 1 |
| Gorelov, D | 1 |
| Gospe, SM | 1 |
| Goyal, NA | 1 |
| Guidon, AC | 1 |
| Guptill, JT | 1 |
| Gutmann, L | 2 |
| Gwathmey, K | 1 |
| Harati, Y | 1 |
| Harper, CM | 1 |
| Hehir, MK | 1 |
| Hobson-Webb, LD | 1 |
| Howard, JF | 1 |
| Jackson, CE | 1 |
| Johnson, N | 1 |
| Jones, SM | 1 |
| Juel, VC | 1 |
| Kaminski, HJ | 1 |
| Karam, C | 1 |
| Kennelly, KD | 1 |
| Khella, S | 1 |
| Khoury, J | 1 |
| Kincaid, JC | 1 |
| Kissel, JT | 1 |
| Kolb, N | 1 |
| Lacomis, D | 1 |
| Ladha, S | 1 |
| Larriviere, D | 1 |
| Lewis, RA | 1 |
| Li, Y | 1 |
| Litchy, WJ | 1 |
| Logigian, E | 1 |
| Lou, JS | 1 |
| MacGowen, DJ | 1 |
| Maselli, R | 1 |
| Massey, JM | 1 |
| Mauermann, ML | 1 |
| Mathews, KD | 1 |
| Meriggioli, MN | 1 |
| Miller, RG | 1 |
| Moon, JS | 1 |
| Mozaffar, T | 1 |
| Nations, SP | 1 |
| Nowak, RJ | 1 |
| Ostrow, LW | 1 |
| Pascuzzi, RM | 1 |
| Peltier, A | 1 |
| Ruzhansky, K | 1 |
| Richman, DP | 1 |
| Ross, MA | 1 |
| Rubin, DI | 1 |
| Russell, JA | 1 |
| Sachs, GM | 1 |
| Salajegheh, MK | 1 |
| Saperstein, DS | 1 |
| Scelsa, S | 1 |
| Selcen, D | 1 |
| Shaibani, A | 1 |
| Shieh, PB | 1 |
| Silvestri, NJ | 1 |
| Singleton, JR | 1 |
| Smith, BE | 1 |
| So, YT | 1 |
| Solorzano, G | 1 |
| Sorenson, EJ | 1 |
| Srinivasen, J | 1 |
| Tavee, J | 1 |
| Tawil, R | 1 |
| Thaisetthawatkul, P | 1 |
| Thornton, C | 1 |
| Trivedi, J | 1 |
| Vernino, S | 1 |
| Wang, AK | 1 |
| Webb, TA | 1 |
| Weiss, MD | 1 |
| Windebank, AJ | 1 |
| Wolfe, GI | 1 |
1 other study available for amifampridine and Neuromuscular Junction Diseases
| Article | Year |
|---|---|
Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Amifampridine; Humans; Neuromuscular Junction Diseases; Orphan Drug Production; Phy | 2016 |